EnviroTech :: Biotech
DSM to Manufacture C. difficile Compound for U.K. Biotech Firm
12:16 AM MDT | June 11, 2010 | Deepti Ramesh
DSM BioSolutions, part of the DSM Pharma cluster, says it has entered into an agreement with biotechnology company Novacta Biosystems (Welwyn Garden City, U.K.) for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds. Financial terms of the deal were not disclosed. DSM has completed the process development and has commenced cGMP-manufacturing of the Novacta compound at its microbial fermentation biotech facility at Capua, Italy. The product will initially be used for pre-clinical and phase I...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee